Advertisement
U.S. markets closed

Journey Medical Corporation (DERM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.6500-0.1000 (-2.67%)
At close: 04:00PM EST
3.4800 -0.17 (-4.66%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.7500
Open3.7100
Bid3.2100 x 1400
Ask3.6200 x 900
Day's Range3.6200 - 3.8000
52 Week Range1.0200 - 8.1100
Volume91,911
Avg. Volume325,290
Market Cap67.556M
Beta (5Y Monthly)0.97
PE Ratio (TTM)N/A
EPS (TTM)-0.6900
Earnings DateMar 20, 2024 - Mar 25, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DERM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Journey Medical Corporation
    Daily – Vickers Top Buyers & Sellers for 10/18/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Zacks

    Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B

    Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.

  • GlobeNewswire

    Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

    If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea NDA submission supported by positive Phase 3 clinical data SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved pre

  • GlobeNewswire

    Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

    Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29SCOTTSDALE, Ariz., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced